List of Aldara drug patents
Aldara is owned by Bausch.
Aldara contains Imiquimod.
Aldara has a total of 2 drug patents out of which 0 drug patents have expired.
Aldara was authorised for market use on 27 February, 1997.
Aldara is available in cream;topical dosage forms.
Aldara can be used as treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sbcc); works through the induction of interferon and other cytokines.
The generics of Aldara are possible to be released after 01 October, 2024.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7696159 | BAUSCH | Treatment for basal cell carcinoma |
Apr, 2024
(1 year, 10 days from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7696159
(Pediatric) | BAUSCH | Treatment for basal cell carcinoma |
Oct, 2024
(1 year, 6 months from now) | |
Drugs and Companies using IMIQUIMOD ingredient
Market Authorisation Date: 27 February, 1997
Treatment: Treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sbcc); Works through the induction of interferon and other cytokines
Dosage: CREAM;TOPICAL
ALDARA family patents
5
United States
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic